No Data
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
Express News | Intensity Therapeutics, Inc. Announces First Patient Dosed in Its Global Randomized, Phase 3 Study (Invincible-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics Files to Sell Common Stock by Selling Stockholders
Express News | Intensity Therapeutics Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
Benchmark: Reiterates Intensity Therapeutics (INTS.US) rating and adjusted from Speculative Buy to Specified Buy with a target price of $12.00.
Benchmark: Reiterates Intensity Therapeutics (INTS.US) rating and adjusted from Speculative Buy to Specified Buy with a target price of $12.00.
No Data